American International Group, Inc. Arcturus Therapeutics Holdings Inc. Transaction History

American International Group, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$31.23 - $42.99 $3,091 - $4,256	-99 Reduced 0.85%	11,491 $388,000
Q4 2023 Feb 13, 2024	SELL	$17.71 - $32.97 $832 - $1,549	-47 Reduced 0.4%	11,590 $365,000
Q3 2023 Nov 13, 2023	BUY	$25.44 - $37.35 $10,532 - $15,462	414 Added 3.69%	11,637 $297,000
Q2 2023 Aug 04, 2023	BUY	$23.94 - $32.36 $1,651 - $2,232	69 Added 0.62%	11,223 $321,000
Q1 2023 May 12, 2023	BUY	$14.72 - $23.97 $3,253 - $5,297	221 Added 2.02%	11,154 $267,000
Q4 2022 Feb 10, 2023	SELL	$14.14 - $23.06 $565 - $922	-40 Reduced 0.36%	10,933 $185,000
Q3 2022 Nov 14, 2022	BUY	$13.05 - $22.13 $2,035 - $3,452	156 Added 1.44%	10,973 $163,000
Q2 2022 Aug 12, 2022	BUY	$12.26 - $31.17 $4,119 - $10,473	336 Added 3.21%	10,817 $170,000
Q1 2022 May 13, 2022	SELL	$17.64 - $39.57 $13,018 - $29,202	-738 Reduced 6.58%	10,481 $283,000
Q4 2021 Feb 11, 2022	SELL	$34.2 - $47.56 $11,457 - $15,932	-335 Reduced 2.9%	11,219 $415,000
Q3 2021 Nov 12, 2021	SELL	$27.88 - $58.25 $7,667 - $16,018	-275 Reduced 2.32%	11,554 $552,000
Q2 2021 Aug 13, 2021	BUY	$25.79 - $42.11 $2,372 - $3,874	92 Added 0.78%	11,829 $400,000
Q1 2021 May 07, 2021	SELL	$38.75 - $86.92 $40,997 - $91,961	-1,058 Reduced 8.27%	11,737 $485,000
Q4 2020 Feb 12, 2021	BUY	$34.61 - $123.66 $111,651 - $398,927	3,226 Added 33.71%	12,795 $555,000
Q3 2020 Nov 04, 2020	BUY	$37.49 - $63.19 $59,759 - $100,724	1,594 Added 19.99%	9,569 $411,000
Q2 2020 Aug 12, 2020	BUY	$12.66 - $58.27 $100,963 - $464,703	7,975 New	7,975 $373,000

186

25.9M

320K

153K

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $617M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.